Hearts and Minds Investments' (ASX:HM1) portfolio declined 8.9% in March, bigger than the MSCI World Index's 5.2% drop in the same month, according to a Friday filing with the Australian bourse.
The decline occurred as equity markets faced volatility during the month amid uncertainties about US trade policies, the filing said.
The investment company also saw the unsuccessful outcome of Opthea's (ASX:OPT) phase 3 clinical trials for its lead drug candidate, OPT-302. This prompted Hearts & Minds to write down its investment to zero.
Before its trading suspension, Opthea represented around 2.4% of Hearts and Minds Investments' portfolio, per a Tuesday statement.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。